For the first-line treatment of metastatic pancreatic cancer, the best first option is a clinical trial, says Ocean, especially for patients who have been diagnosed with an aggressive and hard-to-treat disease.
If a clinical trial is not available or the patient does not want to participate, then a more standard treatment regimen can be considered, such as FOLFIRINOX or gemcitabine and nab-paclitaxel (Abraxane), adds Ocean. Read more . . .